abstract |
The present invention is described in PCT Publication No. WO 2004/105765 as an inhibitor of biological activities mediated by VEGFR3, particularly those mediated by VEGFR3 ligands VEGF-C and / or VEGF-D. It relates to some uses of the described macrocyclic quinazoline derivatives. [Selection figure] None |